Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity

Persistent Newcastle disease virus infection in bladder cancer cells is associated with putative pro-survival and anti-viral transcriptomic changes

A bibliometric review of oncolytic virus research as a novel approach for cancer therapy

MicroRNA-204 plays a role as a tumor suppressor in Newcastle disease virus-induced oncolysis in lung cancer A549 cells

Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus

The oncolytic Newcastle disease virus as an effective immunotherapeutic strategy against glioblastoma

Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged

Oncolytic effects of the recombinant Newcastle disease virus, rAF-IL12, against colon cancer cells in vitro and in tumor-challenged NCr-Foxn1nu nude mice

Newcastle Disease Virus at the Forefront of Cancer Immunotherapy

Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials